Oncomir MicroRNA-346 Is Upregulated in Colons of Patients With Primary Sclerosing Cholangitis.
Adult
Caco-2 Cells
Case-Control Studies
Cholagogues and Choleretics
/ pharmacology
Cholangitis, Sclerosing
/ complications
Colitis, Ulcerative
/ complications
Colon
/ metabolism
Colon, Ascending
Colon, Sigmoid
Colorectal Neoplasms
/ genetics
Cyclin-Dependent Kinase Inhibitor p27
/ drug effects
Female
Gene Expression Regulation
Hep G2 Cells
Humans
Male
MicroRNAs
/ drug effects
Middle Aged
RNA, Ribosomal, 18S
/ genetics
Receptors, Calcitriol
/ drug effects
Tumor Necrosis Factor-alpha
/ drug effects
Up-Regulation
Ursodeoxycholic Acid
/ pharmacology
Young Adult
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
24
1
2020
medline:
20
11
2020
entrez:
24
1
2020
Statut:
ppublish
Résumé
Primary sclerosing cholangitis (PSC) is a cholestatic liver disorder that is frequently associated with ulcerative colitis (UC). Patients with PSC and UC (PSC-UC) have a higher risk of colorectal neoplasia compared with patients with UC. The oncogenic properties of microRNA-346 (miR-346) have been recently reported. We investigated the expression of miR-346 and its 2 target genes, the receptor of vitamin D (VDR), and the tumor necrosis factor-α (TNF-α), which are known to modulate carcinogenesis. Ascending and sigmoid colon biopsies were obtained from patients with PSC, PSC and UC (PSC-UC), UC, and healthy controls (n = 10 in each group). Expressions of VDR, TNF-α, 18S RNA, p27, miR-346, and reference microRNA, miR-191, were evaluated by real-time PCR using human TaqMan Gene Expression and TaqMan MicroRNA Assays. Functional studies with miR-346 mimic and inhibitor were conducted in HepG2 and Caco-2 cells. The effect of ursodeoxycholic acid on miR-346 expression was examined in Caco-2 cells. An increased expression of miR-346 in the ascending colon of PSC-UC was observed (P < 0.001 vs all groups). In patients with UC, an exceptionally low colonic expression of miRNA-346 was accompanied by the extensive upregulation of VDR and TNF-α genes. A functional in vitro analysis demonstrated that inhibition of miR-346 resulted in the upregulation of VDR and TNF-α, whereas the induction of miR-346 activity suppressed VDR, TNF-α, and p27. The upregulation of miRNA-346 in the colon of patients with PSC may be responsible for the disturbance of VDR and TNF-α signaling pathway, which could result in an inadequate suppression of neoplasia.
Identifiants
pubmed: 31972611
doi: 10.14309/ctg.0000000000000112
pmc: PMC7056054
pii: 01720094-202001000-00006
doi:
Substances chimiques
Cholagogues and Choleretics
0
MIRN346 microRNA, human
0
MicroRNAs
0
RNA, Ribosomal, 18S
0
Receptors, Calcitriol
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
VDR protein, human
0
Cyclin-Dependent Kinase Inhibitor p27
147604-94-2
Ursodeoxycholic Acid
724L30Y2QR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00112Références
Lancet. 2013 Nov 9;382(9904):1587-99
pubmed: 23810223
Gastroenterology. 1993 Jan;104(1):145-51
pubmed: 8419237
Int J Mol Sci. 2017 Jan 29;18(2):
pubmed: 28146070
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
J Clin Invest. 2013 Sep;123(9):3983-96
pubmed: 23945234
Am J Pathol. 1992 Mar;140(3):539-44
pubmed: 1372154
J Steroid Biochem Mol Biol. 2015 Apr;148:179-83
pubmed: 25603468
Biomed Pharmacother. 2016 Dec;84:705-713
pubmed: 27701052
World J Gastroenterol. 2015 Nov 21;21(43):12274-82
pubmed: 26604636
Calcif Tissue Int. 2013 Feb;92(2):77-98
pubmed: 22782502
Tumour Biol. 2016 Feb;37(2):2765-71
pubmed: 26408183
Prostate Cancer. 2012;2012:128965
pubmed: 23326670
Cell Cycle. 2009 Mar 1;8(5):736-41
pubmed: 19221487
Oncotarget. 2016 Sep 27;7(39):64371-64379
pubmed: 27608842
Nat Med. 1997 Feb;3(2):231-4
pubmed: 9018245
Gene. 2017 Feb 5;600:21-28
pubmed: 27913185
Am J Gastroenterol. 1997 Aug;92(8):1285-8
pubmed: 9260790
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Oncol Lett. 2017 Sep;14(3):3255-3260
pubmed: 28927074
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):110-7
pubmed: 20134493
Mutat Res. 2005 Jan;589(1):47-65
pubmed: 15652226
Oncology. 2000;58(1):45-51
pubmed: 10644940
PLoS One. 2011;6(5):e19827
pubmed: 21611196
FASEB J. 2016 Mar;30(3):1367-76
pubmed: 26700731
PLoS One. 2010 Oct 05;5(10):
pubmed: 20957151
Int J Mol Sci. 2017 Nov 07;18(11):
pubmed: 29112157
Inflamm Bowel Dis. 2014 Nov;20(11):1910-8
pubmed: 25192497
J Clin Lab Anal. 1999;13(6):291-5
pubmed: 10633297
Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G208-16
pubmed: 17962355
Front Immunol. 2017 Jan 20;7:697
pubmed: 28163705
Scand J Gastroenterol. 2007 Nov;42(11):1312-20
pubmed: 17852866
J Hepatol. 2009 Jan;50(1):158-64
pubmed: 19012991
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Cancers (Basel). 2018 Jan 20;10(1):
pubmed: 29361689
Inflamm Bowel Dis. 2009 Sep;15(9):1331-6
pubmed: 19229982
Int J Cancer. 2016 Mar 1;138(5):1118-28
pubmed: 26413860
Immunol Rev. 2004 Dec;202:275-93
pubmed: 15546400